[Market Focus] Samsung Biologics and Episholdings Weaken Together on First Day After Spin-off and Relisting
After the spin-off and relisting, both Samsung Biologics and the newly established Samsung Episholdings are experiencing declines.
As of 9:54 a.m. on the 24th, Samsung Biologics is trading at 1,669,000 won, down 128,000 won (7.12%) from the previous session. Samsung Episholdings is at 498,500 won, down 112,500 won (18.41%) from its opening price of 611,000 won.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Previously, Samsung Biologics underwent a spin-off into a surviving company (Samsung Biologics), which continues its contract development and manufacturing organization (CDMO) business, and a new company (Samsung Episholdings) responsible for investments and subsidiary management. Samsung Bioepis is in charge of the biosimilar business and new drug development.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.